Trials / Completed
CompletedNCT04323657
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- TCR2 Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This is a Phase 1/2 open-label study to evaluate the safety of autologous genetically engineered TC-110 T cells in patients with aggressive NHL (DLBCL, PMBCL, TFL), high-risk indolent NHL (including MCL), or adult ALL.
Conditions
- Non Hodgkin Lymphoma
- Acute Lymphoblastic Leukemia
- Diffuse Large B Cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TC-110 T Cells | TC-110 T Cells |
| DRUG | Fludarabine | Flu/Cy Lymphodepletion |
| DRUG | Cyclophosphamide | Flu/Cy Lymphodepletion |
Timeline
- Start date
- 2020-03-27
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
- First posted
- 2020-03-26
- Last updated
- 2023-03-16
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04323657. Inclusion in this directory is not an endorsement.